458 related articles for article (PubMed ID: 21611968)
1. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
[TBL] [Abstract][Full Text] [Related]
2. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
3. The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice.
Zheng D; Peng S; Yang SH; Shao ZW; Yang C; Feng Y; Wu W; Zhen WX
Bone; 2012 Jul; 51(1):85-92. PubMed ID: 22551876
[TBL] [Abstract][Full Text] [Related]
4. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
[TBL] [Abstract][Full Text] [Related]
5. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
7. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
[TBL] [Abstract][Full Text] [Related]
8. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
9. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
10. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotective effects of osthole in a mouse model of 5/6 nephrectomy through inhibiting osteoclast formation.
Li X; Xue C; Wang L; Tang D; Huang J; Zhao Y; Chen Y; Zhao D; Shi Q; Wang Y; Shu B
Mol Med Rep; 2016 Oct; 14(4):3769-76. PubMed ID: 27571745
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
Song R; Gu J; Liu X; Zhu J; Wang Q; Gao Q; Zhang J; Cheng L; Tong X; Qi X; Yuan Y; Liu Z
Int J Mol Med; 2014 Sep; 34(3):856-62. PubMed ID: 25017214
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
14. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival.
Ochi H; Hara Y; Tagawa M; Shinomiya K; Asou Y
J Orthop Res; 2010 May; 28(5):657-63. PubMed ID: 19890995
[TBL] [Abstract][Full Text] [Related]
15. GSK-3β inhibition suppresses instability-induced osteolysis by a dual action on osteoblast and osteoclast differentiation.
Amirhosseini M; Madsen RV; Escott KJ; Bostrom MP; Ross FP; Fahlgren A
J Cell Physiol; 2018 Mar; 233(3):2398-2408. PubMed ID: 28731198
[TBL] [Abstract][Full Text] [Related]
16. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
17. Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Dela Cruz A; Grynpas MD; Mitchell J
Am J Physiol Endocrinol Metab; 2016 May; 310(10):E811-20. PubMed ID: 27006198
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin-Knockout Mice Developed Early Onset Root Resorption.
Liu Y; Du H; Wang Y; Liu M; Deng S; Fan L; Zhang L; Sun Y; Zhang Q
J Endod; 2016 Oct; 42(10):1516-22. PubMed ID: 27663616
[TBL] [Abstract][Full Text] [Related]
19. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice.
Kimura M; Miyazawa K; Tabuchi M; Maeda H; Kameyama Y; Goto S
Calcif Tissue Int; 2008 Feb; 82(2):137-47. PubMed ID: 18183447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
